CU
CUE.O
—
NASDAQ
Pharmaceuticals & Medical Research
Cue Biopharma Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
87,5M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-96,7 %
ROE
-100,6 %
Net margin
-96,9 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
250
Day range
$19,75–$21,22
Prev close
$20,03
Open
$19,75
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
Cue Biopharma Inc is a biotechnology company focused on the development of novel therapies for the treatment of cancer, primarily through its proprietary T-cell engager platform.
Business. Cue Biopharma Inc (CUE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target120,00
Analyst recommendations
1 analysts · consensus BuyBuy1
Hold0
Sell0
12-month price target
120,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-100,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CUE.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Cue Biopharma Inc (CUE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDCue Biopharma Inc has a strong liquidity position, with $27.14 million in cash and equivalents, representing 64.3% of its total assets of $42.21 million. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. The current ratio of 2.74 suggests the company is well-positioned to meet its short-term obligations.
The company is currently unprofitable, with a net loss of $26.60 million and an operating loss of $26.55 million. Its return on equity is -100.64%, and return on assets is -63.02%, both significantly below the industry median for biotechnology firms. The price-to-book ratio of 3.12 and price-to-tangible-book ratio of 3.12 suggest the market is valuing the company's intangible assets at a premium, despite its current unprofitability.
Cue Biopharma Inc does not disclose segment or geographic revenue breakdowns in its latest financials, making it difficult to assess revenue concentration or geographic exposure. The company's operations are likely centered in the United States, as is typical for biotechnology firms, but no specific geographic data is available.
The company's revenue of $27.47 million represents a modest base, but with no disclosed historical revenue growth rates, it is unclear whether this reflects a stable or growing business. The company is expected to remain in a development phase, with no indication of near-term revenue growth acceleration.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, with basic and diluted shares outstanding being equal at 3.26 million. No recent dilutive events or forward-looking dilution risks are disclosed in the latest filings.
Recent investor relations data shows a mean price target of $120.00, significantly higher than the current market price of $25.33. However, the mean recommendation of 2.00 (Buy) is supported by only one Buy rating, with no Strong Buy or Hold ratings, suggesting limited analyst confidence in the stock's near-term performance.
Key takeaways
- Cue Biopharma Inc has a strong liquidity position with no long-term debt and a current ratio of 2.74.
- The company is currently unprofitable, with a net loss of $26.60 million and a return on equity of -100.64%.
- The company's market price of $25.33 is significantly below the mean analyst price target of $120.00.
- No segment or geographic revenue breakdown is disclosed, limiting visibility into revenue concentration.
- The company has low dilution risk, with no recent dilutive events or forward-looking dilution risks disclosed.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$26,87
Market cap
$82.5M
Enterprise valueⓘ
$55.3M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
3.1x
P / Tangible bookⓘ
3.1x
Tangible book
$26.4M
Net cashⓘ
$27.1M
Current ratioⓘ
2.7
Debt / equityⓘ
0.0
ROAⓘ
-63.0%
ROEⓘ
-1.0%
Cash conversionⓘ
82.0%
CapEx / revenueⓘ
-0.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs CUE · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+141,1 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+52,8 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-59,6 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+105,7 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+119,6 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+43,1 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-17,40
Predicted surprise
+0,00
Beat probability
45 %
Analysts
1
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -17,40 |
| Revenue | —no estimate | —no estimate | 1,0M USD |
| Operating income | —no estimate | —no estimate | —no estimate |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution1 analysts
Strong buy0
Buy1
Hold0
Sell0
Strong sell0
12-month price target$120,00 · Median $120,00
Low $120,00High $120,00
EPS surprise
+51,7 %
reported vs consensus · beat
Revenue surprise
+2 646,6 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$120,00
Mean$120,00
Median$120,00
High$120,00
Spot$26,87
+346.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-96,7 %Above median
Net Margin-96,9 %Above median
ROE-100,6 %Bottom quartile
Capex / Rev-0,6 %Above median
D/E0,00Above median
Cash Conv0,82Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 3 641 085 sh17 grants13 insiders
- Director, Chief Executive Officer · Common Stock Warrants (Right to Buy) → Common StockAcquired 45 453 @ $11,00purchase · 2026-06-01
- Director, Chief Executive Officer · Pre-Funded Warrants (Right to Buy) → Common StockAcquired 90 906 @ $0,00purchase · 2026-06-01
- Director · Stock Option (Right to Buy) → Common StockAcquired 1 626 @ $21,90grant · 2026-05-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 1 626 @ $21,90grant · 2026-05-30
- Director, CHIEF EXECUTIVE OFFICER · Stock Option (right to buy) → Common StockAcquired 655 074 @ $30,42grant · 2026-05-03
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 200 000 @ $0,29grant · 2026-04-09
- CHIEF BUSINESS OFFICER · Stock Option (right to buy) → Common StockAcquired 250 000 @ $0,29grant · 2026-04-09
- CHIEF DEVELOPMENT OFFICER · Stock Option (right to buy) → Common StockAcquired 100 000 @ $0,29grant · 2026-04-09
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 70 000 @ $0,70grant · 2025-12-03
- Director, CHIEF EXECUTIVE OFFICER · Stock Option (right to buy) → Common StockAcquired 1 875 000 @ $0,72grant · 2025-09-29
- CHIEF DEVELOPMENT OFFICER · Stock Option (right to buy) → Common StockAcquired 50 000 @ $0,72grant · 2025-09-29
- CHIEF BUSINESS OFFICER · Stock Option (right to buy) → Common StockAcquired 125 000 @ $0,72grant · 2025-09-29
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 30 000 @ $0,70grant · 2025-09-26
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Cue Biopharma Inc Market data — financials · 2026-05-27
- Cue Biopharma Inc Market data — analyst estimates · 2026-05-27
- Cue Biopharma Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Shao-lee LinPresident, Chief Executive Officer, Director
Insider activity
Net buying5 buys · 0 sellsnet $100K2 insiders · last 365d
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 327 537 · 2026-05-03
- Director · Common StockBought 86 947 @ $0,32$28K · 2025-12-30
- Director · Common StockBought 4 229 @ $0,31$1K · 2025-12-30
- Director · Common StockBought 78 116 @ $0,31$24K · 2025-12-30
- Director · Common StockBought 77 417 @ $0,30$23K · 2025-12-30
- Director · Common StockBought 77 148 @ $0,30$23K · 2025-12-30
Short positioning
307.9Kshares short+3.3% vs prior
2.22days to cover
49.6%short of daily vol
1.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CUE.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 2.74xDerived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 40.3%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 168.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 61.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 61.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 7.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 31.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 51.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 195.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 4.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 34.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 20.8%Derived (calculated)
- Net margin (FY 2025-12-31): -96.9%Derived (calculated)
- Return on equity (FY 2025-12-31): -100.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -63.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.60xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 36.0%Derived (calculated)
- Capex (annual): USD 177KSEC XBRL filing
- Cash & equivalents (annual): USD 27.14MSEC XBRL filing
- Operating income (annual): USD -26.55MSEC XBRL filing
- Total operating expenses (annual): USD 54.02MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Revenue (annual): USD 27.47MSEC XBRL filing
- Net income (annual): USD -26.6MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-01 00:00 UTCINSIDER2 insider transactions — 2026-06 2 derivative
2026-06-01INSIDERLin Shao-Lee acquired 45.5k sh Common Stock Warrants (Right to Buy) — Director, Chief Executive Officer
2026-06-01INSIDERLin Shao-Lee acquired 90.9k sh Pre-Funded Warrants (Right to Buy) — Director, Chief Executive Officer
2026-05-30 00:00 UTCINSIDER4 insider transactions — 2026-05 3 derivative
2026-05-30INSIDERMeehan Viola Mong acquired 1.6k sh Stock Option (Right to Buy) — Director
2026-05-30INSIDERCamardo Daniel A. acquired 1.6k sh Stock Option (Right to Buy) — Director
2026-05-03INSIDERLin Shao-Lee transacted 327.5k sh — Director, CHIEF EXECUTIVE OFFICER
2026-05-03INSIDERLin Shao-Lee acquired 655.1k sh Stock Option (right to buy) — Director, CHIEF EXECUTIVE OFFICER
2026-04-09 00:00 UTCINSIDER3 insider transactions — 2026-04 3 derivative
2026-04-09INSIDERSandercock Colin acquired 200.0k sh Stock Option (right to buy) — SVP, GENERAL COUNSEL
2026-04-09INSIDERWarren Lucinda acquired 250.0k sh Stock Option (right to buy) — CHIEF BUSINESS OFFICER
2026-04-09INSIDERBaker Daniel G. acquired 100.0k sh Stock Option (right to buy) — CHIEF DEVELOPMENT OFFICER
2026-01-02 00:00 UTCINSIDER6 insider transactions — 2026-01 6 derivative
2026-01-02INSIDERBroadfoot Jill Marie acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERKiener Peter A acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERGarzone Pamela acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERMorich Frank acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERVerheyen Patrick acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERSarraf Pasha acquired 24.4k sh Stock Option (right to buy) — Director
2025-12-30 00:00 UTCINSIDER6 insider transactions — 2025-12 1 derivative
2025-12-30INSIDERSarraf Pasha bought 86.9k sh — Director ~$28k
2025-12-30INSIDERSarraf Pasha bought 4.2k sh — Director ~$1k
2025-12-30INSIDERSarraf Pasha bought 78.1k sh — Director ~$24k
2025-12-30INSIDERSarraf Pasha bought 77.4k sh — Director ~$23k
2025-12-30INSIDERSarraf Pasha bought 77.1k sh — Director ~$23k
2025-12-03INSIDERSandercock Colin acquired 70.0k sh Stock Option (right to buy) — SVP, GENERAL COUNSEL
2025-09-29 00:00 UTCINSIDER4 insider transactions — 2025-09 4 derivative
Showing the 40 most recent of 45 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage